Victoza, PCOS, and autoimmune disease: sorting GLP-1 hype from evidence

What did @blissfullybakedchelsea actually say?

Chelsea documents switching from Mounjaro (tirzepatide) to Victoza (liraglutide) after losing 65 pounds on Mounjaro over roughly a year, then regaining about 15 pounds in four months off medication. She explains the switch as insurance-driven, not clinical. She also frames her use of GLP-1 medication as medically justified by Hashimoto's thyroiditis, hypothyroidism, and a new suspected PCOS diagnosis, saying these conditions cause insulin resistance that makes weight loss "impossible" through diet and exercise alone. Then, on camera, she injects Victoza at the 0.6 mg starting dose without an alcohol swab, noting she "didn't get any" in her supply.

To her credit, she messaged her prescriber mid-video to confirm her dose rather than guessing. That's a small but real point in her favor. The broader claims about insulin resistance and autoimmune overlap, though, deserve a closer look.

Does the science back this up?

Mostly, yes, but with important caveats. The connection between Hashimoto's, hypothyroidism, PCOS, and insulin resistance is real and well-documented. The claim that exercise alone won't move the scale for someone with untreated or undertreated metabolic dysfunction is also supported, though it's overstated when presented as absolute.

Hypothyroidism slows basal metabolic rate and impairs glucose metabolism. A 2018 meta-analysis by Brandt et al. in Thyroid confirmed that even subclinical hypothyroidism is associated with insulin resistance independent of BMI. PCOS, separately, is characterized by hyperandrogenism and insulin resistance in 50-70% of cases, per Diamanti-Kandarakis and Dunaif (2012) in Endocrine Reviews. The co-occurrence of autoimmune thyroid disease and PCOS is also not rare: a 2019 study by Sinha et al. in Clinical Endocrinology found Hashimoto's in roughly 27% of PCOS patients studied, compared to about 8% of controls. So Chelsea's framing of "one autoimmune disease often means more" is directionally accurate.

Where it gets murkier: liraglutide (Victoza) is FDA-approved for type 2 diabetes and, at a higher dose (3 mg, branded as Saxenda), for chronic weight management. Victoza is dosed up to 1.8 mg for glycemic control. Using it off-label for weight loss in someone without type 2 diabetes is common but not identical to the on-label weight management indication.

What did they get wrong (or right)?

The no-alcohol-swipe injection is worth addressing directly: current CDC and manufacturer guidelines do recommend cleaning injection sites with an alcohol swab before subcutaneous injection, though the clinical risk from skipping once is low for most healthy skin. It's still not best practice to model this on a platform with 8,000 viewers, some of whom may be immunocompromised.

Her claim that she "can exercise until I pass out every single day and still not lose weight" is emotionally real but physiologically overstated. Insulin resistance makes weight loss harder, not impossible through exercise. A 2020 RCT by Aguiar et al. in Obesity Reviews found resistance training meaningfully improved insulin sensitivity in PCOS patients even without medication. Saying exercise has zero effect misrepresents the evidence and may discourage people from a genuinely useful tool.

She also conflates Victoza and Saxenda as essentially the same drug, which they are chemically (both liraglutide), but the FDA-approved doses for weight loss (Saxenda at 3 mg) are higher than typical Victoza doses. This distinction matters if someone's insurer covers one and not the other.

What she got right: the titration start at 0.6 mg is exactly correct per prescribing guidelines. She confirmed it with her doctor in real time. And her description of Mounjaro as a once-weekly injection versus Victoza as daily is accurate.

What should you actually know?

If you have Hashimoto's, hypothyroidism, or PCOS and are struggling with weight despite genuine effort, you are not imagining it. The metabolic overlap between these conditions is real, and GLP-1 receptor agonists have emerging evidence in these populations beyond just blood sugar control. A 2022 review by Jensterle et al. in International Journal of Molecular Sciences found liraglutide reduced weight and improved insulin sensitivity markers in women with PCOS specifically.

That said, medication access should not look like this: figuring out your dose mid-video, injecting without proper site prep, and switching drugs because of insurance coverage rather than clinical reasoning. These are systemic failures in how GLP-1s are being prescribed and covered in the U.S., and Chelsea is caught in them, but viewers should not take her trial-and-error process as a model.

Mounjaro (tirzepatide) and Victoza (liraglutide) are not equivalent. Tirzepatide is a dual GIP/GLP-1 agonist. Liraglutide is a GLP-1 agonist only. The mechanisms differ, and so do the average weight loss outcomes in clinical trials. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 22.5% body weight reduction with tirzepatide. SCALE Obesity (Pi-Sunyer et al., 2015, NEJM) showed about 8% with liraglutide 3 mg. Chelsea should know going in that she may see different results, and that's not a personal failure.